186 related articles for article (PubMed ID: 24196512)
1. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
Kmietowicz Z
BMJ; 2013 Nov; 347():f6696. PubMed ID: 24196512
[No Abstract] [Full Text] [Related]
2. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges.
Kay M
BMJ; 2013 May; 346():f3536. PubMed ID: 23723460
[No Abstract] [Full Text] [Related]
3. US drug companies paid $15bn in fines for fraudulent marketing in past five years.
Tanne JH
BMJ; 2010 Dec; 341():c7360. PubMed ID: 21177361
[No Abstract] [Full Text] [Related]
4. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
5. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
6. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
Benko LB
Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
[No Abstract] [Full Text] [Related]
7. Helping your patients avoid counterfeit medicines.
Teichman PG
Fam Pract Manag; 2007 Mar; 14(3):33-5. PubMed ID: 17408128
[No Abstract] [Full Text] [Related]
8. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
9. US judge fines Johnson & Johnson $1.1bn for misleading marketing of risperidone.
Tanne JH
BMJ; 2012 Apr; 344():e2772. PubMed ID: 22508952
[No Abstract] [Full Text] [Related]
10. Former Johnson and Johnson executives are convicted over off label marketing.
Dyer O
BMJ; 2016 Jul; 354():i4179. PubMed ID: 27469393
[No Abstract] [Full Text] [Related]
11. RFID implementation not moving fast enough, FDA says.
Young D
Am J Health Syst Pharm; 2006 Mar; 63(6):500-2. PubMed ID: 16522876
[No Abstract] [Full Text] [Related]
12. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
13. EPA charges illegal claim for antibacterial-impregnated consumer products.
Pugliese G; Favero MS
Infect Control Hosp Epidemiol; 1998 Feb; 19(2):140. PubMed ID: 9510115
[No Abstract] [Full Text] [Related]
14. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
15. Johnson & Johnson pays $181m for misleading marketing of risperidone.
Tanne JH
BMJ; 2012 Sep; 345():e5916. PubMed ID: 22945959
[No Abstract] [Full Text] [Related]
16. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
Murdey J
Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
[TBL] [Abstract][Full Text] [Related]
17. Prescription drugs marketed in the United States should be approved by the FDA.
Shepherd MD; Curtiss FR
J Manag Care Pharm; 2003; 9(4):366-7. PubMed ID: 14613456
[TBL] [Abstract][Full Text] [Related]
18. Former drug execs lose appeal. Bid for re-entry to Medicare is denied.
Rhea S
Mod Healthc; 2010 Dec 20-27; 40(51):14. PubMed ID: 21344720
[No Abstract] [Full Text] [Related]
19. FTC cracks down on false dietary supplement ads.
Am J Health Syst Pharm; 2001 Aug; 58(15):1382, 1384. PubMed ID: 11494778
[No Abstract] [Full Text] [Related]
20. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
